Recent News

• 12.10.2025 - IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.”
• 12.09.2025 - IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial
• 12.02.2025 - IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer’s Disease
• 11.25.2025 - IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer’s and Aging Trends
• 11.18.2025 - IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
• 11.13.2025 - USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer’s Disease and Central Nervous System Disorders
• 11.10.2025 - IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
• 11.03.2025 - IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
• 10.22.2025 - IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant”

Recent Filings

• 12.05.2025 - EFFECT Notice of Effectiveness
• 12.03.2025 - S-3/A Registration statement under Securities Act of 1933
• 11.17.2025 - S-3 Registration statement under Securities Act of 1933
• 11.14.2025 - 8-K Current report
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.14.2025 - EX-99.1 EX-99.1
• 10.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2025 - 4 Statement of changes in beneficial ownership of securities